Acceleron Pharma Inc. (XLRN)
(Delayed Data from NSDQ)
$41.49 USD
+1.00 (2.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $41.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[XLRN]
Reports for Purchase
Showing records 1 - 20 ( 109 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
3Q21 Results; Closing of Acquisition by Merck Expected Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Highlights from PAH Evolving Landscape KOL Call: Need for Novel Mechanisms
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Acquisition by Merck Announced; Downgrade to Neutral and Raise PT to Merck''s $180 Bid
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
2Q21 Results; Solid Reblozyl Sales Could Improve With Further Europe Penetration and Expanding Addressable Markets
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Building for 2021 and Beyond; Highlights From Acceleron R&D Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Compelling Results From the Phase 2 BEYOND Study Presented at EHA 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Sotatercept Data at ATS 2021 Looks Solid; Phase 3 Registrational STELLAR Study Underway
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department